The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Sports
  • Books
  • Entertainment

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
  • CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
  • Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
  • Ezra Wohlgelernter Installed Philadelphia Bar Association Chancellor
  • Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Mark Schork Elected to Executive Committee of Philadelphia Bar Association Young Lawyers Division
  • Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • Nonprofit Operations' First-Of-Its-Kind Job Portal Empowers Nonprofit Job Seekers
  • Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
  • Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
  • Artificial Intelligence Leader Releases Children's Book on Veterans Day
  • KDG Recognized on the Clutch 1000 List for 2025
  • SNS Research Group has published its flagship report, "Dermatological Drugs Market: 2025–2035"
  • Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
  • CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
  • The Rise of Experience Gifting: Families Choosing Memories Over More Stuff This Christmas
  • Pittsburgh Family Law Firm Pollock Begg Elevates Two Attorneys to Partner Ranks
  • Innovu Launches Auto Analysis, an AI Feature That Explains Healthcare Data in Plain Language
  • Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 911
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 263
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 114
  • Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • NorthSky Celebrates One-Year Anniversary
  • Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market

Similar on PennZone

  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us